New pill targets Hard-to-Treat KRAS cancers in early human trial

NCT ID NCT06243354

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests an experimental drug, HYP-2090PTSA, in people with advanced solid tumors that have a specific genetic change called KRAS mutation. The trial has two parts: first, finding the safest dose, and then testing how well that dose works in certain cancers. About 257 adults with advanced cancer will take part. The goal is to control the disease, not to cure it.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TOLERABILITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Fujian Provincial Cancer Hospital

    RECRUITING

    Fuzhou, Fujian, 350000, China

    Contact

  • Hunan Provincial Cancer Hospital

    NOT_YET_RECRUITING

    Changsha, Hunan, 410000, China

    Contact

  • Shandong Provincial Cancer Hospital

    NOT_YET_RECRUITING

    Jinan, Shandong, 250000, China

    Contact

  • Shanghai Pulmonary Hospital

    RECRUITING

    Shanghai, Shanghai Municipality, 200000, China

    Contact

  • The first Hospital of China Medical University

    NOT_YET_RECRUITING

    Shenyang, Liaoning, 110000, China

    Contact

  • West China Hospital of Sichuan University

    RECRUITING

    Chengdu, Sichuan, 610000, China

    Contact